Is NEWP undervalued? Our fair value estimate
New Pacific Metals Corp. · Basic Materials · ASE
How we got here
The estimate is computed from NEWP's reported fundamentals, with a growth assumption that is deliberately capped: small changes to an uncapped growth or terminal assumption can justify any price, and a number that can justify anything means nothing. These are the inputs the model holds for NEWP today; the exact method, and where it goes wrong, is on the methodology page.
Wall Street's published earnings growth forecast, used as context for the capped growth assumption, never swallowed whole.
Persistent high returns on capital are what a moat looks like in the accounts, and they feed the moat score alongside the valuation.
A volatility measure against the wider market. A jumpier share earns a larger discount for risk, which lowers the estimate.
Wall Street's number, next to ours
The mean analyst price target for NEWP is USD7.12 across 1 analysts, which implies +71.1% from the current price. Our estimate is USD1.63. They answer different questions: an analyst target is a 12-month price prediction averaged across banks; ours is a model's view of what the business is worth, with every assumption published. When they disagree, at least one of us is wrong.
The belief gap: what growth this price asks you to believe
Run our DCF backwards and every price becomes a growth assumption. One axis compares them: today's market price, the entry prices implied by super investors' 13F filings, the mean analyst target, and the growth our own model funds. The gap between the market's marker and the cohort's markers is the growth you are being asked to believe that informed buyers did not need.
Today's price asks you to believe about 28.6% annual cash-flow growth. Millennium Management's Q4 2025 entry only needed about 24.0%. Our model funds 5.0%.
Millennium Management's Q4 2025 filing implies an average entry near $3.51, which implied about 24.0% annual growth under our model (low confidence).
Renaissance Technologies's Q1 2026 filing implies an average entry near $4.14, which implied about 28.5% annual growth under our model.
Arrowstreet Capital's Q4 2025 filing implies an average entry near $3.50, which implied about 23.9% annual growth under our model (low confidence).
Two Sigma Investments's Q4 2025 filing implies an average entry near $3.51, which implied about 24.0% annual growth under our model (low confidence).
Entry prices are filing-implied averages (reported position value divided by reported shares for the quarter a position was opened or materially increased), not actual cost bases; 13Fs lag by up to 45 days. How the Belief Gap is computed.
Common questions
Is New Pacific Metals Corp. (NEWP) undervalued?
On our model, NEWP at USD4.16 trades 61% above our fair value estimate of USD1.63, so it screens as overvalued today. That is one model's answer, not a recommendation: a fair value estimate is an argument about the future, and the market is frequently right about why something is cheap.
What is the fair value of NEWP?
Our current fair value estimate for New Pacific Metals Corp. is USD1.63 per share. For comparison, the mean Wall Street analyst price target is USD7.12 across 1 analysts; that is their number, computed differently from ours. The estimate moves as prices and fundamentals move.
How is NEWP's fair value calculated?
From New Pacific Metals Corp.'s reported fundamentals: earnings power, a deliberately capped growth assumption, and a discount for balance sheet and volatility risk. The full method, including its known weaknesses, is published on our methodology page, and the interactive Valuation Lab lets you change every assumption and watch the value move.
Disagree with an assumption? Good. The Valuation Lab on the NEWP app page puts every input of this model on a slider, including a reverse DCF that shows the growth the market is currently pricing in.
A fair value estimate is a model output computed from company filings and market data, refreshed daily; quotes are delayed. It is educational information, not financial advice and not a recommendation to buy or sell anything. Read the full disclaimer.